NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Polaris Peptides? Mail in a sample (US only) and let us test it.

Test my supply
+1 more ↓
63%
Finnrick rating
#395 of 500 ranked vendors
66 of 99 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Polaris Peptides has its clearest purity-focus support in Tirzepatide and a small but clean Mazdutide record, while Semaglutide improves after early misses. The catalog is dispersed: BPC-157 repeatedly misses purity, GHK-Cu has quantity-control outliers, and mixed batch IDs temper otherwise recent, broad evidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: Polaris Peptides

Corporate filings and lab-submission records trace Polaris to a Nevada LLC and a US controller, while the storefront map splits between a gated dot-com and a probable but unconfirmed dot-io channel. The report follows lookalikes, COA labs, payment rails, and reseller clues.

26 pages5 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.63
81%
5
2
Tirzepatide
$9.90
80%
16
3
Retatrutide
$11.90
77%
29
4
Mazdutide
$15.00
69%
3
5
Semaglutide
$9.35
68%
19
6
PT-141
$3.40
66%
8
7
Survodutide
$12.75
52%
6
8
BPC-157
$5.40
36%
17
9
CJC-1295
$5.40
32%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%11 Aug 2025: 66%11 Aug 2025: 67%11 Aug 2025: 66%11 Aug 2025: 66%11 Aug 2025: 66%11 Aug 2025: 66%11 Aug 2025: 66%11 Aug 2025: 67%12 Aug 2025: 66%12 Aug 2025: 66%12 Aug 2025: 66%12 Aug 2025: 66%12 Aug 2025: 66%12 Aug 2025: 66%12 Aug 2025: 65%12 Aug 2025: 65%12 Aug 2025: 65%15 Aug 2025: 65%15 Aug 2025: 65%19 Aug 2025: 65%19 Aug 2025: 66%19 Aug 2025: 65%19 Aug 2025: 65%1 Oct 2025: 65%1 Oct 2025: 65%9 Oct 2025: 65%7 Nov 2025: 65%25 Nov 2025: 64%7 Jan 2026: 64%19 Jan 2026: 64%13 May 2026: 65%13 May 2026: 65%9 Aug 2026: 66%9 Aug 2026: 65%9 Aug 2026: 65%9 Aug 2026: 64%15 Sep 2026: 64%15 Sep 2026: 64%16 Sep 2026: 63%16 Sep 2026: 63%17 Nov 2026: current 63%66%64%63%Aug 25Nov 26
Peptide testing

Ordered peptides from Polaris Peptides? Mail in a sample (US only) and let us test it.

Test my supply
Polaris Peptides test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
16 Sep 2026
Fail
BPC-157
lab nameView COA
16 Sep 2026
Fail
Tirzepatide
lab nameView COA
15 Sep 2026
Pass
GHK-Cu
lab nameView COA
15 Sep 2026
Fail
BPC-157
lab nameView COA
9 Aug 2026
Fail
BPC-157
lab nameView COA
9 Aug 2026
Pass
BPC-157
lab nameView COA
9 Aug 2026
Fail
Semaglutide
lab nameView COA
9 Aug 2026
Fail
Semaglutide
lab nameView COA
13 May 2026
Pass
Retatrutide
lab nameView COA
13 May 2026
Fail
BPC-157
lab nameView COA
1-10 of 107

About Polaris Peptides test results from Finnrick

Polaris Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 107 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Polaris Peptides peptides in this dataset are BPC-157 (17 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 107 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Polaris Peptides? Mail in a sample (US only) and let us test it.

Test my supply